← Back to guidelines
Pediatrics11 papers

Pancreatic agenesis, holoprosencephaly syndrome

Last edited: 4/15/2026

Overview

Pancreatic agenesis associated with holoprosencephaly syndrome is a rare genetic disorder characterized by developmental defects in both the pancreas and forebrain, often linked to mutations in genes critical for embryonic development such as CNOT1 1.

Diagnosis

  • Genetic Testing: Identification of CNOT1 mutations, particularly c.1603C>T (p.Arg535Cys), is crucial 1.
  • Imaging Studies: MRI or CT scans to assess brain anomalies indicative of holoprosencephaly 1.
  • Pancreatic Function Tests: Evaluation for absence or severe dysfunction of pancreatic tissue 1.
  • Phenotypic Criteria: Beyond CNOT1 mutations, consider a broader spectrum including craniofacial anomalies, polydactyly, and brain defects like microcephaly and agenesis of the corpus callosum 2.
  • Management

  • Supportive Care: Focus on managing symptoms and complications such as feeding difficulties and neurological deficits 1.
  • Nutritional Support: Pancreatic enzyme replacement therapy and specialized nutritional plans for pancreatic insufficiency 1.
  • Neurological Interventions: Tailored to individual brain anomalies, potentially including surgical interventions for specific defects 1.
  • Genetic Counseling: Essential for families to understand recurrence risks and implications 1.
  • Special Populations

  • Pediatrics: Early intervention for developmental delays and feeding issues is critical 1.
  • Comorbidities: Consider additional skeletal and craniofacial anomalies requiring multidisciplinary care 13.
  • Key Recommendations

  • Genetic Testing for CNOT1 Mutations: Essential for diagnosis of pancreatic agenesis with holoprosencephaly syndrome (Evidence: Strong 1).
  • Comprehensive Imaging: Utilize MRI or CT to fully assess brain malformations (Evidence: Moderate 1).
  • Multidisciplinary Support: Implement care involving pediatricians, neurologists, and geneticists to address varied clinical manifestations (Evidence: Expert opinion 13).
  • References

    1 De Franco E, Watson RA, Weninger WJ, Wong CC, Flanagan SE, Caswell R et al.. A Specific CNOT1 Mutation Results in a Novel Syndrome of Pancreatic Agenesis and Holoprosencephaly through Impaired Pancreatic and Neurological Development. American journal of human genetics 2019. link 2 Lurie IW, Wulfsberg EA. "Holoprosencephaly-polydactyly" (pseudotrisomy 13) syndrome: expansion of the phenotypic spectrum. American journal of medical genetics 1993. link 3 Martin AO, Perrin JC, Muir WA, Ruch E, Schafer IA. An autosomal dominant midline cleft syndrome resembling familial holoprosencephaly. Clinical genetics 1977. link

    Original source

    1. [1]
      A Specific CNOT1 Mutation Results in a Novel Syndrome of Pancreatic Agenesis and Holoprosencephaly through Impaired Pancreatic and Neurological Development.De Franco E, Watson RA, Weninger WJ, Wong CC, Flanagan SE, Caswell R et al. American journal of human genetics (2019)
    2. [2]
      "Holoprosencephaly-polydactyly" (pseudotrisomy 13) syndrome: expansion of the phenotypic spectrum.Lurie IW, Wulfsberg EA American journal of medical genetics (1993)
    3. [3]
      An autosomal dominant midline cleft syndrome resembling familial holoprosencephaly.Martin AO, Perrin JC, Muir WA, Ruch E, Schafer IA Clinical genetics (1977)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG